Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04234568 · ClinicalTrials.gov registry record · Phase 1

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

A Phase 1 study of Metastatic Digestive System Neuroendocrine Neoplasm and Metastatic Neuroendocrine Tumor, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
31
Enrollment target
11
Study locations

NCT04234568 is a Phase 1 study of Metastatic Digestive System Neuroendocrine Neoplasm and Metastatic Neuroendocrine Tumor that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04234568, a Phase 1 study of Metastatic Digestive System Neuroendocrine Neoplasm and Metastatic Neuroendocrine Tumor, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
31 participants
Enrollment target
11
Study locations

Study Summary

This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. Giving triapine and lutetium Lu 177 dotatate together may work better to treat patients with neuroendocrine tumors.

Conditions Studied

Metastatic Digestive System Neuroendocrine Neoplasm Metastatic Neuroendocrine Tumor

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • DRUG Lutetium Lu 177 Dotatate
  • DRUG Triapine

Study Locations (11)

Florida

  • Mayo Clinic in Florida - Jacksonville
  • Moffitt Cancer Center - Tampa

Arizona

  • Mayo Clinic Hospital in Arizona - Phoenix

California

  • City of Hope Comprehensive Cancer Center - Duarte

Illinois

  • Northwestern University - Chicago

Kentucky

  • University of Kentucky/Markey Cancer Center - Lexington

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic in Rochester - Rochester

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2020-07-20
Est. Completion 2026-03-14
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04234568

The ClinicalTrials.gov registry entry for NCT04234568 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Digestive System Neuroendocrine Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT04234568 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT04234568 about?

NCT04234568 is a clinical study titled "Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors". This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lute...

What is the current status of trial NCT04234568?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2020-07-20. Estimated completion is 2026-03-14.

What conditions does trial NCT04234568 study?

This clinical trial studies the following conditions: Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor.

What interventions are being tested in trial NCT04234568?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Lutetium Lu 177 Dotatate (DRUG), Triapine (DRUG).

Who is sponsoring clinical trial NCT04234568?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04234568 being conducted?

This trial has 11 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Digestive System Neuroendocrine Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Digestive System Neuroendocrine Neoplasm

All registered trials for this condition

Metastatic Neuroendocrine Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.